Schlosser Mario sold $25.9M of OSCR

Schlosser Mario sold 880,000 shares of Oscar Health, Inc. (OSCR) at an average of $29.38 ($28.95–$30.09, $25.85M total) across 3 trades on 2026-06-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schlosser Mario
Published Jun 25, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 25, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OSCR
Neutral
medium confidence
Mentioned
$OSCR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRNeutralLow
01

Why it matters

The key new information is the disclosed sale size, execution window (2026-06-23), and the confirmation that it was under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor OSCR for any follow-on insider activity, but the 10b5-1 structure typically dampens interpretive impact.

03

What to watch

The filing does not indicate whether other insiders or institutions are buying/selling, nor does it provide any new operational or financial guidance.

Relevance 6/10Novelty 5/10Timing: after-hours/filing update (Form 4 filed 2026-06-25)

Background

This is an SEC Form 4 insider transaction disclosure for Oscar Health, Inc. (OSCR).

Company-level read

Ticker impact

$OSCRNeutralMedium confidence
Context

Oscar Health director Mario Schlosser sold 880,000 shares in open-market transactions totaling about $25.85M under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any impact is likely short-lived sentiment drift.

Evidence & confidence

Form 4 discloses transaction size and timing (6/23) and confirms it was executed under a pre-arranged 10b5-1 plan, which typically limits interpretive weight versus discretionary selling.

Market effects

Limited read-across to the digital health/insurtech peer group; this is company-specific insider activity.

None.

None.

Counterpoint

Because the trades were executed under a 10b5-1 plan, the sale may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • Oscar Health, Inc.

    Subject of the Form 4 insider sale; director Mario Schlosser sold 880,000 shares.

  • Mario Schlosser

    Director who executed open-market sales totaling ~$25.85M under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$OSCRHighAI 8/10

What Oscar Health (OSCR) Said on Its Q3 Earnings Call

Oscar Health (OSCR) reported Q3 improvements in medical loss ratio (84%) and SG&A expense ratio (14%). The company raised its 2026 outlook, expecting $850M-$950M in earnings from operations and $19B-$19.3B in revenue. Membership grew 27% YoY to 2.7M, but is expected to decline to 2.5M by year-end due to disenrollments. Oscar plans to expand its footprint and products for 2027.

$OSCRMed

Oscar Health Inc (OSCR) Q3 2026 Earnings Call Highlights: Record Profitability, Raised

Oscar Health (OSCR) reported Q3 2026 earnings with record profitability and raised guidance. Membership declined due to CMS reviews, with more disenrollments expected. Q4 SG&A expenses are projected to rise due to seasonal spending. CEO Mark Bertolini and CFO Richard Blackley discussed market share gains, utilization trends, and CMS program integrity initiatives. The company anticipates stable membership and market growth despite competitive pressures and regulatory uncertainties.

$OSCRHighAI 8/10

Oscar Health (OSCR) Q3 2026 Earnings Call Transcript

Oscar Health (OSCR) reported Q3 2026 revenue of $5.1B, up 70% YoY, with membership at 2.7M, up 27% YoY. Net income was $167.3M, reversing a prior-year loss. The company raised full-year guidance for revenue, earnings, and adjusted EBITDA. Management highlighted expansion into new markets, product launches, and operational efficiencies.

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.